Genmab A/S

34.18+0.5800+1.73%Vol 505.35K1Y Perf 52.91%
Apr 9th, 2021 16:00 DELAYED
BID33.07 ASK34.85
Open34.09 Previous Close33.60
Pre-Market- After-Market-
 - -  - -%
Target Price
42.00 
Analyst Rating
Strong Buy 1.21
Potential %
22.88 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     63.44
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     89.03
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap22.42B 
Earnings Rating
Price Range Ratio 52W %
54.11 
Earnings Date
5th May 2021

Today's Price Range

33.8134.29

52W Range

21.6244.83

5 Year PE Ratio Range

31.80106.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
3.76%
1 Month
6.35%
3 Months
-17.40%
6 Months
-8.73%
1 Year
52.91%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GMAB34.180.58001.73
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 20200.120.1416.67
Q03 20200.080.1362.50
Q02 20200.880.76-13.64
Q01 20200.020.06200.00
Q04 20190.360.34-5.56
Q03 20190.081.261.48K
Q02 20190.070.20185.71
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th May 2021
Estimated EPS Next Report-
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume505.35K
Shares Outstanding655.87M
Trades Count4.83K
Dollar Volume40.78M
Avg. Volume643.57K
Avg. Weekly Volume398.66K
Avg. Monthly Volume608.92K
Avg. Quarterly Volume658.08K

Genmab A/S (NASDAQ: GMAB) stock closed at 34.18 per share at the end of the most recent trading day (a 1.73% change compared to the prior day closing price) with a volume of 506.52K shares and market capitalization of 22.42B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 781 people. Genmab A/S CEO is Jan G. J. van de Winkel.

The one-year performance of Genmab A/S stock is 52.91%, while year-to-date (YTD) performance is -15.94%. GMAB stock has a five-year performance of %. Its 52-week range is between 21.62 and 44.83, which gives GMAB stock a 52-week price range ratio of 54.11%

Genmab A/S currently has a PE ratio of 28.60, a price-to-book (PB) ratio of 7.14, a price-to-sale (PS) ratio of 14.99, a price to cashflow ratio of 21.30, a PEG ratio of 2.32, a ROA of 26.28%, a ROC of 36.73% and a ROE of 28.75%. The company’s profit margin is 48.69%, its EBITDA margin is 72.60%, and its revenue ttm is $1.46 Billion , which makes it $2.23 revenue per share.

Of the last four earnings reports from Genmab A/S, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genmab A/S’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Genmab A/S is Strong Buy (1.21), with a target price of $42, which is +22.88% compared to the current price. The earnings rating for Genmab A/S stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genmab A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genmab A/S has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.90, ATR14 : 1.45, CCI20 : -89.06, Chaikin Money Flow : -0.13, MACD : -2.43, Money Flow Index : 25.79, ROC : -16.76, RSI : 29.65, STOCH (14,3) : 16.28, STOCH RSI : 0.78, UO : 43.16, Williams %R : -83.72), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genmab A/S in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
5 (71.43 %)
Moderate Buy
2 (28.57 %)
2 (28.57 %)
2 (28.57 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.21
Strong Buy
1.21
Strong Buy
1.21

Genmab A/S

Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

CEO: Jan G. J. van de Winkel

Telephone: +45 70202728

Address: Kalvebod Brygge 43, Copenhagen V 1560, , DK

Number of employees: 781

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

News

Stocktwits